Juan M. E. Harrison
Directeur/Membre du Conseil chez Bridge Medicines LLC
Profil
Juan M.
E.
Harrison is currently a Director at Bridge Medicines LLC.
Previously, he held positions as President, Chief Executive Officer & Director at Imidomics, Inc., Principal at ALZA Corp., Connetics Corp., and XenoPort, Inc., Vice President at Takeda Ventures, Inc., and Principal at PowderJect Vaccines, Inc. He was also a Partner at Propharma Partners International, Inc. in 2007.
Harrison received his undergraduate degree from Santa Clara University.
Postes actifs de Juan M. E. Harrison
| Sociétés | Poste | Début |
|---|---|---|
Bridge Medicines LLC
 Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Juan M. E. Harrison
| Sociétés | Poste | Fin |
|---|---|---|
| Propharma Partners International, Inc. | Corporate Officer/Principal | 31/12/2007 |
Imidomics, Inc.
 Imidomics, Inc. BiotechnologyHealth Technology Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves. | Directeur Général | - |
| PowderJect Vaccines, Inc. | Corporate Officer/Principal | - |
| ALZA CORPORATION | Corporate Officer/Principal | - |
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | - |
Formation de Juan M. E. Harrison
| Santa Clara University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Connetics Corp.
Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Takeda Ventures, Inc.
 Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Finance |
| PowderJect Vaccines, Inc. | |
| Propharma Partners International, Inc. | |
Bridge Medicines LLC
Bridge Medicines LLC Pharmaceuticals: MajorHealth Technology Bridge Medicines LLC operates as a drug discovery company. It provides spanning therapeutic areas including infectious disease, oncology, neuropsychiatry, and rare diseases. The company was founded on November 1, 2016 and is headquartered in New York, NY. | Health Technology |
Imidomics, Inc.
Imidomics, Inc. BiotechnologyHealth Technology Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves. | Health Technology |